Press release
Fulcrum Therapeutics to Present Preclinical Data for EED Inhibitor FTX-6274 at European Society for Medical Oncology (ESMO) Congress 2025
― Preclinical data of FTX-6274 suggests potential for the treatment of castration resistant prostate cancer ― CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE)
About this update from Fulcrum Therapeutics, Inc.
[{"type":"text","content":"― Preclinical data of FTX-6274 suggests potential for the treatment of castration resistant prostate cancer ― CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that it will present preclinical data for FTX-6274, an oral embryonic ectoderm development, or EED, inhibitor, in castration-resistant prostate cancer. Fulcrum will present these data at the ESMO Congress 2025 being held October 17-21, 2025, in Berlin, Germany. “We are encouraged by these findings, which highlight the potential of EED inhibition beyond our current hematology programs,” said Jeff Jacobs, Chief Scientific Officer. “Given Fulcrum’s strategic focus on non-malignant hematologic diseases, a strategic partnership may provide the best path to advance FTX-6274 for oncology indications.” Presentation details are as follows: Title: FTX-6274, an EED Inhibitor, Demonstrates Robust Efficacy in Castration Resistant Prostate Cancer (CRPC)Poster ID: 2504PFormat: PosterFirst Author: Suchi Raghunathan, Senior Scientist, In Vivo PharmacologyPresentation Date and Time: Saturday, October 18, 2025, between 12:00-12:45 PM CEST Following congress publication, the poster will be available on the Publications & Presentations Page of Fulcrum’s website at https://www.fulcrumtx.com. About Fulcrum TherapeuticsFulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin (HbF) for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn. Forward-Looking StatementsThis press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than stat...